Clinical Trial

Consumer Health Study Aims to Evaluate the Safety, Tolerability and Impact of ED02 Probiotic Supplement on Gastrointestinal Outcomes

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2026 (before its estimated June 17, 2026 completion). Its status may not reflect the trial's current state.
Summary
The Study Team identified Bifidobacterium pseudocatenulatum ED02 as a safe and effective probiotic strain isolated from a healthy human donor. Research by the Study Team indicates that this strain lacks harmful genetic traits and can successfully mitigate infections from hypervirulent pathogens like Klebsiella pneumoniae without adverse effects.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-04-02
Trial Details
NCT Number NCT07423897
Lead Sponsor Synbiotic Health
Collaborators: People Science, Inc.
Conditions Gastrointestinal, Gut Health
Enrollment 35 participants
Start Date 2026-02-02
Primary Completion 2026-06-17 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-01